Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 239.74 Billion KRW | 12.32% |
| 2022 | 213.45 Billion KRW | 7.54% |
| 2021 | 198.47 Billion KRW | -9.84% |
| 2020 | 220.13 Billion KRW | 15.02% |
| 2019 | 191.38 Billion KRW | 17.92% |
| 2018 | 162.3 Billion KRW | -3.79% |
| 2017 | 168.69 Billion KRW | 35.25% |
| 2016 | 124.73 Billion KRW | 6.49% |
| 2015 | 117.12 Billion KRW | 34.36% |
| 2014 | 87.17 Billion KRW | -10.91% |
| 2013 | 97.85 Billion KRW | -21.26% |
| 2012 | 124.27 Billion KRW | 17.85% |
| 2011 | 105.45 Billion KRW | -14.2% |
| 2010 | 122.9 Billion KRW | -2.8% |
| 2009 | 126.44 Billion KRW | 7.37% |
| 2008 | 117.76 Billion KRW | 21.66% |
| 2007 | 96.79 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 212.91 Billion KRW | -3.88% |
| 2024 Q1 | 221.51 Billion KRW | -7.6% |
| 2023 Q3 | 241.31 Billion KRW | 6.2% |
| 2023 Q4 | 239.74 Billion KRW | -0.65% |
| 2023 FY | 239.74 Billion KRW | 12.32% |
| 2023 Q1 | 209.13 Billion KRW | -2.02% |
| 2023 Q2 | 227.22 Billion KRW | 8.65% |
| 2022 FY | 213.45 Billion KRW | 7.54% |
| 2022 Q2 | 183.41 Billion KRW | -3.7% |
| 2022 Q1 | 190.45 Billion KRW | -4.04% |
| 2022 Q4 | 213.45 Billion KRW | 14.55% |
| 2022 Q3 | 186.34 Billion KRW | 1.6% |
| 2021 Q2 | 203.84 Billion KRW | 0.1% |
| 2021 FY | 198.47 Billion KRW | -9.84% |
| 2021 Q1 | 203.63 Billion KRW | -7.49% |
| 2021 Q3 | 202.99 Billion KRW | -0.42% |
| 2021 Q4 | 198.47 Billion KRW | -2.23% |
| 2020 FY | 220.13 Billion KRW | 15.02% |
| 2020 Q4 | 220.13 Billion KRW | 6.19% |
| 2020 Q1 | 191.13 Billion KRW | -0.13% |
| 2020 Q3 | 207.3 Billion KRW | 4.94% |
| 2020 Q2 | 197.55 Billion KRW | 3.36% |
| 2019 Q4 | 191.38 Billion KRW | 3.93% |
| 2019 FY | 191.38 Billion KRW | 17.92% |
| 2019 Q1 | 163.86 Billion KRW | 0.96% |
| 2019 Q2 | 181.34 Billion KRW | 10.66% |
| 2019 Q3 | 184.15 Billion KRW | 1.55% |
| 2018 Q4 | 162.3 Billion KRW | -1.01% |
| 2018 Q1 | 163.71 Billion KRW | -2.95% |
| 2018 FY | 162.3 Billion KRW | -3.79% |
| 2018 Q2 | 162.15 Billion KRW | -0.95% |
| 2018 Q3 | 163.96 Billion KRW | 1.12% |
| 2017 Q2 | 124.26 Billion KRW | 0.6% |
| 2017 FY | 168.69 Billion KRW | 35.25% |
| 2017 Q4 | 168.69 Billion KRW | 29.02% |
| 2017 Q3 | 130.74 Billion KRW | 5.22% |
| 2017 Q1 | 123.52 Billion KRW | -0.97% |
| 2016 Q3 | 124.4 Billion KRW | -1.81% |
| 2016 FY | 124.73 Billion KRW | 6.49% |
| 2016 Q1 | 122.85 Billion KRW | 4.89% |
| 2016 Q2 | 126.7 Billion KRW | 3.13% |
| 2016 Q4 | 124.73 Billion KRW | 0.26% |
| 2015 Q1 | 84.87 Billion KRW | -2.63% |
| 2015 FY | 117.12 Billion KRW | 34.36% |
| 2015 Q4 | 117.12 Billion KRW | -4.43% |
| 2015 Q3 | 122.54 Billion KRW | 43.54% |
| 2015 Q2 | 85.37 Billion KRW | 0.59% |
| 2014 Q1 | 94.52 Billion KRW | -3.4% |
| 2014 FY | 87.17 Billion KRW | -10.91% |
| 2014 Q2 | 96.45 Billion KRW | 2.05% |
| 2014 Q4 | 87.17 Billion KRW | -9.94% |
| 2014 Q3 | 96.79 Billion KRW | 0.35% |
| 2013 Q4 | 97.85 Billion KRW | -12.18% |
| 2013 FY | 97.85 Billion KRW | -21.26% |
| 2013 Q1 | 124.48 Billion KRW | 0.17% |
| 2013 Q2 | 119.82 Billion KRW | -3.75% |
| 2013 Q3 | 111.42 Billion KRW | -7.01% |
| 2012 FY | 124.27 Billion KRW | 17.85% |
| 2012 Q4 | 124.27 Billion KRW | 0.0% |
| 2012 Q1 | 99.6 Billion KRW | 0.0% |
| 2011 FY | 105.45 Billion KRW | -14.2% |
| 2011 Q3 | 106.45 Billion KRW | -4.17% |
| 2011 Q1 | 125.15 Billion KRW | 1.83% |
| 2011 Q2 | 111.08 Billion KRW | -11.24% |
| 2010 Q3 | 129.65 Billion KRW | 0.94% |
| 2010 Q1 | 126.1 Billion KRW | -0.27% |
| 2010 Q2 | 128.44 Billion KRW | 1.85% |
| 2010 FY | 122.9 Billion KRW | -2.8% |
| 2010 Q4 | 122.9 Billion KRW | -5.2% |
| 2009 FY | 126.44 Billion KRW | 7.37% |
| 2009 Q4 | 126.44 Billion KRW | 1.81% |
| 2009 Q3 | 124.2 Billion KRW | 4.05% |
| 2009 Q2 | 119.36 Billion KRW | 1.65% |
| 2009 Q1 | 117.42 Billion KRW | -0.29% |
| 2008 Q2 | 97.7 Billion KRW | 1.39% |
| 2008 Q1 | 96.36 Billion KRW | -0.45% |
| 2008 Q3 | 97.16 Billion KRW | -0.55% |
| 2008 Q4 | 117.76 Billion KRW | 21.2% |
| 2008 FY | 117.76 Billion KRW | 21.66% |
| 2007 Q3 | 97.03 Billion KRW | 2.1% |
| 2007 Q1 | 89.99 Billion KRW | 0.0% |
| 2007 Q2 | 95.03 Billion KRW | 5.6% |
| 2007 FY | 96.79 Billion KRW | 0.0% |
| 2007 Q4 | 96.79 Billion KRW | -0.24% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -20.954% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 87.75% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 72.663% |
| HANDOK Inc. | 790.33 Billion KRW | 69.665% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -40.515% |
| Yuhan Corporation | 2814.07 Billion KRW | 91.48% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 81.771% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -156.471% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 87.718% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 48.871% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -108.524% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -1.352% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 31.184% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -20.954% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 42.807% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 52.029% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 59.323% |
| JW Holdings Corporation | 1176.26 Billion KRW | 79.618% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 60.778% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 82.905% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 62.832% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 31.517% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -55.638% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 35.322% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 50.804% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -20.954% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 77.761% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 86.457% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 62.832% |
| Yuhan Corporation | 2814.07 Billion KRW | 91.48% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 72.756% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -5.801% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 75.874% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 62.832% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 42.904% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 48.866% |
| CKD Bio Corp. | 293.78 Billion KRW | 18.394% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 52.806% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 57.565% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 40.246% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 31.517% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 83.534% |
| Boryung Corporation | 922.36 Billion KRW | 74.007% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 45.815% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 48.871% |
| JW Lifescience Corporation | 255.83 Billion KRW | 6.289% |